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bjectives The pivotal TAXUS IV (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a
ingle Paclitaxel-Eluting Stent) trial evaluated the long-term safety and effectiveness of the
aclitaxel-eluting stent (PES) compared with an otherwise identical bare-metal stent (BMS) in a rela-
ively uncomplicated population of patients with a single de novo lesion in a native coronary vessel,
reated between March and July 2002.
ackground Long-term follow-up is required to determine whether the early safety and efﬁcacy of
rug-eluting stents are maintained.
ethods The primary end point of this prospective, randomized, double-blind trial was 9-month
schemia-driven target vessel revascularization (TVR) for PES versus the BMS control. Follow-up was
omplete in 1,230 (95.1%) of 1,294 randomized evaluable patients at 5 years.
esults Compared with BMS, PES signiﬁcantly reduced TVR at 9 months (12.1% vs. 4.7%; p 
.0001); this beneﬁt was maintained through 5 years (27.4% vs. 16.9%; p  0.0001), given compara-
le TVR rates for BMS and PES between years 1 and 5 (4.1%/year vs. 3.3%/year; respectively, p 
.16). Similar patterns were observed for composite major adverse cardiac events (MACE) (32.8%
MS vs. 24.0% PES, p  0.0001 at 5 years). Stent thrombosis was comparable for PES and BMS at
months (0.8% BMS vs. 0.8% PES; p  0.98) and at 5 years (2.1% BMS vs. 2.2% PES, p  0.87). The
verall revascularization beneﬁts of PES were consistent across multiple subgroups, including sex,
iabetes, left anterior descending artery lesion location, reference vessel diameter, lesion length, and
ultiple stents.
onclusions These 5-year results demonstrate the long-term safety and sustained efﬁcacy of PES com-
ared with BMS in patients with noncomplex lesions. (TAXUS IV-SR: Treatment of De Novo Coronary Dis-
ase Using a Single Paclitaxel-Eluting Stent; NCT00292474) (J Am Coll Cardiol Intv 2009;2:1248–59)
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1249he TAXUS IV (TAXUS IV-SR: Treatment of De
ovo Coronary Disease Using a Single Paclitaxel-
luting Stent) prospective randomized clinical trial com-
ared the Taxus Express2 (Boston Scientific Corp.,
atick, Massachusetts) paclitaxel-eluting stent (PES) to
visually indistinguishable bare-metal stent (BMS) in
,326 randomized patients with noncomplex de novo
esions in a single native coronary artery, representing the
ivotal trial for U.S. approval. The primary end point
nalysis found that PES significantly reduced the rate of
schemia-driven target vessel revascularization (TVR) at
months compared with BMS, with a comparable safety
rofile (1). These favorable early results, however, do not
ddress concerns regarding subsequent potential safety
isks (e.g., increased mortality or stent thrombosis [ST]) with
rug-eluting stents over longer-term follow-up (2–4).
The current study presents the final (5-year) follow-up
ssessment of safety and efficacy data for the TAXUS IV study.
lthough subsequent trials have evaluated the Taxus Express
tent in more complex anatomy (TAXUS V) (5), in “real
orld” use (ARRIVE [TAXUS Peri-Approval Registry: A
ulti-center Safety Surveillance] 1 and 2) (6), in left main
nd/or 3-vessel disease (SYNTAX [SYNergy Between PCI
ith TAXUS and Cardiac Surgery]) (7), in acute myocardial
nfarction (HORIZONS-AMI [Harmonizing Outcomes With
evascularization and Stents in Acute Myocardial Infarction]) (8),
s well as the same drug and polymer on other stent geometries
Taxus Liberte–ATLAS [9], and Taxus Element–PERSEUS),
he final 5-year follow-up of TAXUS IV represents the longest
nd most complete study of this drug-eluting stent that has
een implanted in more than 5 million patients worldwide.
ethods
he TAXUS IV was a prospective, randomized, double-blind,
ontrolled trial designed to evaluate the efficacy and safety of
he TAXUS Express PES by 1:1 randomization against an
therwise identical BMS. Detailed methods for this study have
een previously published (1) and are briefly summarized here.
tudy population. Eligible patients were 18 years with
table or unstable angina or provokable ischemia due to a single
e novo lesion 10 to 28 mm in length and 50% stenosis in
native coronary artery of diameter 2.5 to 3.75 mm that
ould be covered by a single stent. A total of 1,326 patients
ere enrolled in the trial, including 154 patients with lesions
24 mm who received a 32-mm stent when it became
vailable in the latter part of the study. This study was
upport from Boston Scientific and Cordis. Dr. Stone is an advisory board member fo
oard members for Boston Scientific. Dr. O’Shaughnessey is a consultant/advisory b
cientific. Dr. Turco is a Speakers’ Bureau member/advisory board member/consult
mployees of Boston Scientific Corporation, Inc. Dr. Donald Baim passed away uneanuscript received August 4, 2009; revised manuscript received October 6, 2009, accepteonducted in accordance with the principles delineated by
he Declaration of Helsinki and all local regulations. The
tudy protocol was approved by the institutional review
oard at each site before patient enrollment. All patients
rovided written informed consent.
andomization and study treatment. Eligible patients were
andomized in a double-blind fashion, stratified by the
resence or absence of medically treated diabetes (patients
eing treated with insulin and/or oral hypoglycemic medi-
ations) and vessel size (3.0 mm vs. 3.0 mm), to either
slow-release PES (TAXUS Express, Boston Scientific
orp.) or an otherwise identical uncoated BMS (Express,
oston Scientific). Patients were pretreated with aspirin 325
g and clopidogrel 300 mg before catheterization and were
reated after the procedure with aspirin 325 mg daily
ndefinitely and clopidogrel 75
g daily for at least 6 months
er the TAXUS Directions For
se (10). Clinical follow-up was
cheduled for 1, 4, and 9 months
nd yearly thereafter for a total
f 5 years.
nd points. The primary end
oint of the trial was the inci-
ence of ischemia-driven TVR
t 9 months. Secondary end
oints included target lesion re-
ascularization (TLR; stented
egment 5 mm margins); non-
arget lesion target vessel revas-
ularization (non-TL TVR),
yocardial infarction (MI);
eath; major adverse cardiac
vent (MACE), defined as a
omposite of cardiac death, MI,
nd TVR; and ST. This trial was
onducted before the publication
f the Academic Research Con-
ortium (ARC) consensus defi-
itions of ST (11), but all potential ST events were
ubsequently retrospectively adjudicated by a clinical events
ommittee masked to treatment allocation according to
oth the per-protocol (1) and ARC definitions. The per-
rotocol definition of ST was nearly identical to the ARC
efinite plus probable definition and included angiographic
but not pathologic) confirmation of ST presenting in
oncordance with acute coronary syndrome, acute MI in the
istribution of the treated vessel, or unexplained death
ton Scientific and Abbott Vascular. Drs. Cox and Hermiller are consultants/advisory
ember, a Speakers’ Bureau member, and has received research support from Boston
r Boston Scientific, Medtronic, and Cordis. Drs. Bowman and Baim are full-time
dly on November 6, 2009.
Abbreviations and
Acronyms
ARC  Academic Research
Consortium
BMS  bare-metal stent(s)
MACE  major adverse
cardiac events
non-TL TVR  non-target
lesion target vessel
revascularization
PES  paclitaxel-eluting
stent(s)
RVD  reference vessel
diameter
ST  stent thrombosis
TLR  target lesion
revascularization
TVR  target vessel
revascularization
VLST  very late (Academic
Research Consortium
definite/probable) stent
thrombosisd October 8, 2009.
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1250ithin 30 days after procedure (1). The timing of ST was
efined as acute (0 to 24 h), subacute (24 h to 30 days), late
31 to 365 days), or very late (365 days). In a subset of
atients prospectively assigned to receive 9-month angiog-
aphy, quantitative coronary angiography was used to mea-
ure absolute lesion length, reference vessel diameter
Figure 1. Patient Flow
Patient disposition to 5 years in the TAXUS IV trial. BMS  bare-metal stent(s); MI
diameter.RVD), minimal lumen diameter, and percent diameter
tenosis.
tatistical analyses. The statistical analysis plan prespecified
n intent-to-treat analysis for all end points through the first
years of follow-up. Patients who did not receive a study
tent (e.g., because of inability to cross the lesion with the
ocardial infarction; PES  paclitaxel-eluting stent(s); RVD  reference vessel my
eluting stent(s).
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 1 2 , 2 0 0 9 Ellis et al.
D E C E M B E R 2 0 0 9 : 1 2 4 8 – 5 9 The TAXUS IV 5-Year Clinical Results
1251Figure 2. Duration of Antiplatelet TherapyPercent of patients coTable 1. Baseline Patient Demographic Data and Lesion Characteristics
Parameter BMS (n  643) PES (n  651) p Value
Male 72.2% (464/643) 71.7% (467/651) 0.86
Age (yrs) 62.1 11.0 (643) 62.8 11.2 (651) 0.21
Caucasian 89.3% (574/643) 88.9% (579/651) 0.85
Previous PCI 32.0% (204/637) 29.5% (191/647) 0.33
Previous CABG 9.3% (60/643) 9.8% (64/651) 0.76
Previous MI 29.9% (192/643) 30.6% (199/651) 0.78
Congestive heart failure 7.5% (48/643) 5.4% (35/651) 0.13
Ejection fraction (%) 55.5 10.5 (634) 55.3 10.0 (639) 0.70
Unstable angina 32.7% (210/643) 35.8% (233/651) 0.24
Current smoker 20.1% (129/643) 23.7% (154/651) 0.12
Diabetes requiring medication 25.3% (163/643) 23.3% (152/651) 0.40
Insulin-requiring 8.4% (54/643) 7.7% (50/651) 0.64
Noninsulin-requiring 17.0% (109/643) 15.7% (102/651) 0.53
Hyperlipidemia requiring medication 65.6% (422/643) 64.7% (421/651) 0.72
Hypertension requiring medication 69.1% (444/643) 71.0% (462/651) 0.45
History of peripheral vascular disease 10.1% (65/643) 9.4% (61/651) 0.65
History of transient ischemic attack 4.0% (26/643) 3.2% (21/651) 0.43
Treated multiple-vessel disease* 17.7% (114/643) 20.6% (134/651) 0.19
History of cerebrovascular accident 3.4% (22/643) 4.8% (31/651) 0.22
Lesion length (mm) 13.4 6.2 (639) 13.3 6.1 (645) 0.93
Reference vessel diameter (mm) 2.8 0.5 (641) 2.8 0.5 (649) 0.81
Minimum lumen diameter (mm) 1.0 0.3 (641) 0.9 0.3 (649) 0.17
Diameter stenosis (%) 65.5 10.7 (641) 66.5 10.7 (649) 0.10
*Patients with nontarget vessels treated during index procedure.
BMS bare-metal stent(s); CABG coronary artery bypass graft; MImyocardial infarction; PCI percutaneous intervention; PES paclitaxel-ntinuing dual antiplatelet therapy over time. *p  0.05. Abbreviations as in Figure 1.
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1252tent due to calcification, tortuosity, and so forth) were not
ollowed beyond 2 years, per protocol; therefore, all long-
erm follow-up analyses were performed on the safety
opulation (i.e., those who received either a PES or BMS).
inary or categorical variables are presented as percentages
nd were compared with the chi-square test or Fisher exact
Figure 3. MACE and ARC ST to 5 Years
Kaplan-Meier estimates of (A) target vessel revascularization (TVR); (B) target le
(non-TL TVR); (D) MI; (E) cardiac death; (F) overall major adverse cardiac event
probable (ARC ST-D/P); and (H) ARC-ST deﬁnite (ARC ST-Def) only. Abbreviations asest. Continuous variables are presented as mean  SD and
ere compared with Student t test.
The MACE and its components were evaluated with
escriptive statistics, Kaplan-Meier estimates, and the log-
ank test. Annualized hazard rates were also calculated
eparately for MACE and its components with the person-
evascularization (TLR); (C) non-target lesion target vessel revascularization
CE); (G) Academic Research Consortium deﬁned stent thrombosis deﬁnite/sion r
s (MAin Figure 1.
Table 2. Cumulative 5-Year Kaplan-Meier Rates, Annualized Hazard Rates, and Hazard Ratios With 95% CIs for PES and BMS
Year 0 to 1 Years 1 to 5
Annualized Hazard Rate, %/yr
(95% CI)
Hazard Ratio
(95% CI) p Value
Annualized Hazard Rate, %/yr
(95% CI)
Hazard Ratio
(95% CI) p Value
Cumulative 5-Year Kaplan-Meier
Event Rate (%)
BMS
(n  643)
PES
(n  651)
BMS
(n  625)
PES
(n  632)
BMS
(n  643)
PES
(n  651) p Value
TVR 18.7 (15.2–22.2) 7.1 (5.0–9.2) 0.38 (0.3–0.5) 0.0001 4.1 (3.2–4.9) 3.3 (2.5–4.0) 0.80 (0.6–1.1) 0.16 27.4 16.9 0.0001
TLR 16.4 (13.1–19.6) 4.3 (2.7–5.9) 0.26 (0.2–0.4) 0.0001 2.0 (1.4–2.6) 1.5 (1.0–2.0) 0.77 (0.5–1.2) 0.26 20.5 9.1 0.0001
Non-TL TVR 3.2 (1.8–4.6) 2.9 (1.5–4.2) 0.89 (0.5–1.7) 0.73 2.2 (1.6–2.8) 1.8 (1.2–2.3) 0.82 (0.5–1.2) 0.35 10.4 9.1 0.47
MI 4.9 (3.1–6.6) 3.6 (2.1–5.0) 0.73 (0.4–1.3) 0.25 0.8 (0.4–1.2) 1.0 (0.6–1.5) 1.32 (0.7–2.4) 0.37 7.4 7.2 0.87
QWMI 0.3 (-0.1–0.8) 0.8 (0.1–1.5) 2.5 (0.5–12.8) 0.26 0.2 (0–0.4) 0.2 (0–0.4) 0.99 (0.3–3.4) 0.98 1.1 1.4 0.63
NQWMI 4.6 (2.9–6.2) 2.7 (1.4–4.0) 0.60 (0.3–1.1) 0.09 0.7 (0.3–1.0) 0.9 (0.5–1.2) 1.32 (0.7–2.6) 0.42 6.6 5.9 0.60
Death (all-cause) 2.2 (1.1–3.4) 2.4 (1.2–3.5) 1.06 (0.5–2.2) 0.87 2.4 (1.8–3.0) 2.0 (1.5–2.6) 0.84 (0.6–1.2) 0.39 11.2 10.0 0.49
Cardiac death 1.6 (0.6–2.6) 1.4 (0.5–2.3) 0.89 (0.4–2.2) 0.80 0.8 (0.4–1.1) 0.8 (0.4–1.1) 0.98 (0.5–1.9) 0.96 4.5 4.4 0.85
MACE 23.1 (19.1–27.0) 11.2 (8.6–13.9) 0.49 (0.4–0.7) 0.0001 5.3 (4.3–6.3) 4.4 (3.6–5.3) 0.84 (0.6–1.1) 0.20 32.8 24.0 0.0001
Per protocol ST 0.8 (0.1–1.5) 0.6 (0–1.2) 0.79 (0.2–2.9) 0.72 0 (0–0.1) 0.2 (0–0.4) 4.93 (0.6–42.2) 0.11 0.9 1.4 0.46
ARC ST-deﬁnite/probable 1.1 (0.3–1.9) 0.8 (0.1–1.5) 0.71 (0.2–2.2) 0.55 0.3 (0.1–0.5) 0.4 (0.1–0.6) 1.49 (0.5–4.2) 0.45 2.1 2.2 0.87
ARC ST-deﬁnite 0.8 (0.1–1.5) 0.5 (0–1.0) 0.59 (0.1–2.5) 0.47 0.1 (0–0.3) 0.2 (0–0.4) 1.65 (0.4–6.9) 0.49 1.3 1.3 0.98
Values for annualized hazard rates are expressed as percent/year (95% confidence interval [CI]).
ARC Academic Research Consortium; MACEmajor adverse cardiac events; NQWMI non–Q-wavemyocardial infarction; QWMIQ-wavemyocardial infarction; TLR target lesion revascularization; TVR target vessel revascularization; ST stent thrombosis;
other abbreviations as in Table 1.
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1254ime method and expressed as the event rate/100 patient-
ears for the time periods 0 to 1 year and between 1 and 5
ears (12). In this analysis, patients with multiple events
ccurring in both time periods were considered to have the
vent in each time period. Baseline predictors of outcomes
t 5 years were evaluated with logistic regression with
ald’s chi-square test and included all baseline and clinical
ariables, treatment assignments, and procedural variables.
he results are expressed as odds ratios with 95% confidence
ntervals. All p values are 2-sided. All statistical analyses
ere performed with SAS System software, version 8.2 or
bove (SAS Institute, Inc., Cary, North Carolina).
esults
atients and antiplatelet therapy. A total of 1,326 patients
ere initially enrolled in this trial (Fig. 1). Twelve patients
ere deregistered, and 20 patients did not receive a study
tent; these 32 patients were not followed beyond 2 years,
er the protocol design. Deregistered patients did not have
study stent placement attempted; reasons for deregistra-
ion included appropriate study stent size not available (n 
), inability to pass lesion with balloon (n 3), pre-stenting
omplications (n  3), inclusion/exclusion criteria violation
Figure 4. Hazard Rates for TLR in High-Risk Subgroups
Hazard rates for target lesion revascularization (TLR) according to age, sex, me
stents. *By quantitative coronary angiography. ‡Cox’s model. CI  conﬁdence
tions as in Figure 1.n  2), and patient withdrew consent (n  1). Reasons for
onplacement of study stents included inability of the stent
o cross the lesion (n  12), lesion characteristics did not
llow for placement of a study stent (e.g., vessel diameter
ncreased to 4.0 mm after pre-dilation) (n  4), nonde-
loyed stent due to vasospasm caused by guidewire (n  1),
nd patients found not to meet inclusion criteria after
andomization (n  3). Therefore, the predefined safety
opulation used to analyze long-term results consisted of
,294 patients (651 PES and 643 BMS). Clinical follow-up
t 5 years was 95.1% (1,230 of 1,294) complete and did not
iffer significantly between groups (Fig. 1).
Among the safety population, baseline patient and lesion
haracteristics were similar between those who received a
ES and those who received a BMS (Table 1). Immediately
fter procedure, nearly all patients were treated with dual
ntiplatelet therapy, and this was continued through at least
he first 4 months of the study (Fig. 2). At 9 months after
rocedure, 95% were taking aspirin and approximately
0% of patients in each group were still receiving dual
ntiplatelet therapy. Given the double-blind nature of the
tudy, there was no significant difference in the percentage
f patients receiving dual antiplatelet therapy between
treated diabetes, lesion location, vessel size, lesion length (LL), and multiple
al; HR  hazard ratio; LAD  left anterior descending artery; other abbrevia-dically
interv
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1255roups at any point during study follow-up, although rates
f thienopyridine therapy at 4 months and of aspirin therapy
t 3 years were briefly different. At 5 years, 90% of
atients in both groups were taking aspirin, but dual
ntiplatelet therapy had fallen to 32% of the BMS patients
nd 31% of the PES patients.
linical outcomes. At the 9-month primary end point time
oint, the use of PES compared with BMS significantly
ecreased the rate of ischemia-driven TVR (p  0.001) (1).
his difference was then maintained throughout follow-up,
ith 16.9% of PES patients versus 27.4% of BMS patients
aving undergone TVR by 5 years (hazard ratio: 0.56, 95%
onfidence interval: 0.44 to 0.71; p  0.0001) (Fig. 3A).
imilar results were observed for TLR, with a significant
enefit for PES at 9 months, followed by a low and
elatively stable annualized hazard rate of 2.0%/year for
MS and 1.5%/year for PES between years 1 and 5 (Fig.
B, Table 2). The annual TVR rates were slightly higher
han those of TLR between years 1 and 5 (4.1%/year for
Figure 5. Effect of Routine Angiography on Clinical Outcomes
Rates of MACE, MACE components, and ARC ST to 5 years in patients with and
abbreviations as in Figures 1 and 3.MS and 3.3%/year for PES), due to similar ongoing
isease progression in the remainder of the stented vessel
non-TL TVR) for both PES and BMS (Fig. 3C, Table 2)
13). The Kaplan-Meier curves for the safety end points are
early superimposable for PES and BMS, with no signifi-
ant difference for either cardiac death (p  0.85) or MI
p  0.87) (Figs. 3D and 3E). Therefore, the sustained
rst-year reductions in TLR and TVR translated into an
ngoing significant (p 0.0001) reduction in the composite
ACE end point through 5 years for PES treatment (Fig.
F, Table 2), with no evidence of late “catch-up” in adverse
vents by the PES group.
The 5-year cumulative incidence of all-cause death was
1.2% for BMS and 10.0% for PES (Kaplan-Meier esti-
ates; log-rank p value  0.49), corresponding to an
nnualized mortality of approximately 2%/year for both
ES and BMS. At 9 months, total ARC ST (definite/
robable) was 0.8% in both groups (p  0.98). The
bserved rates of ARC ST (either definite/probable or
out routine angiography for (A) PES and (B) BMS. CD  cardiac death; otherwith
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1256efinite only) were not statistically significantly different
etween BMS and PES at any point during follow-up (Figs.
G and 3H). Acute ARC definite/probable ST (binary
ates) occurred in 0.3% (2 of 643) of BMS patients versus
% (0 of 651) of PES patients (p  0.25); subacute ST
ccurred in 0.5% (3 of 641) of BMS patients and 0.3% (2 of
50) of PES patients (p  0.68); late ST in 0.5% (3 of 639)
f BMS patients and 0.5% (3 of 648) of PES patients (p 
.99); and very late ARC definite/probable ST (VLST)
ccurred in 1.1% (7 of 625) of BMS versus 1.4% (9 of 632)
f PES patients (p  0.63). The relative risk for VLST
ARC definite/probable) in PES versus BMS was 1.27
95% confidence interval: 0.48 to 3.39; p  0.63), corre-
ponding to an annualized hazard rate for VLST of 0.3%/
ear for BMS and of 0.4%/year for PES (p 0.45) between
ears 1 and 5. No PES-related ARC definite/probable ST
ccurred after day 1,334; the last ST in the BMS arm
ccurred on day 1,835.
The decreased risk of TLR at 5 years for PES compared
ith BMS was consistent across multiple subgroups, includ-
ng sex, diabetes, left anterior descending artery lesion
Table 3. Baseline Factors Associated With MACE at 5 Years
Baseline Variable* Coefficient
Odds Ratio
(95% CI) p Value
Overall population
Diabetes requiring medication 0.46 1.59 (1.20–2.11) 0.001
Treatment with PES 0.40 0.67 (0.52–0.87) 0.002
Lesion angulation 0.01 0.99 (0.98–1.00) 0.002
Pre-treatment reference diameter, mm 0.40 0.67 (0.51–0.88) 0.005
Pre-treatment % diameter stenosis 0.02 0.98 (0.97–1.00) 0.01
Number of stents 0.41 1.51 (1.04–2.21) 0.03
ACC/AHA Class C 0.29 1.33 (0.97–1.83) 0.07
Vessel tortuosity 0.44 1.56 (0.95–2.56) 0.08
Family history of CAD 0.23 1.26 (0.97–1.63) 0.08
Patients treated with BMS
Acute gain 0.54 0.59 (0.37–0.92) 0.02
Lesion angulation 0.01 0.99 (0.98–1.00) 0.02
Number of stents 0.56 1.74 (1.07–2.85) 0.03
Pre-treatment reference diameter, mm 0.42 0.65 (0.44–0.97) 0.04
Number of lesions treated 0.51 0.60 (0.37–0.97) 0.04
Family history of CAD 0.31 1.37 (0.96–1.96) 0.09
Patients treated with PES
Diabetes requiring medication 0.59 1.80 (1.18–2.75) 0.006
Age 0.02 0.98 (0.96–0.99) 0.01
Lesion calciﬁcation† 0.59 1.81 (1.12–2.92) 0.02
Maximum stent expansion diameter 0.59 0.55 (0.32–0.95) 0.03
Angina class 3 or 4 0.46 1.58 (1.04–2.40) 0.03
Chronic heart failure 0.80 2.22 (1.02–4.85) 0.046
Hypertension treatment 0.41 1.51 (0.96–2.37) 0.07
*All variables with p 0.10 are shown. †Severe calcification was an exclusion criterion.
ACC American College of Cardiology; AHA American Heart Association; CAD coronary
artery disease; other abbreviations as in Tables 1 and 2.ocation, baseline RVD, lesion length, and single versusultiple stents, with comparable and significant reductions
n TLR for each of the subgroups (Fig. 4).
ffect of routine angiographic follow-up on clinical outcomes.
n this study, 56% (722 of 1,294) of patients were assigned
o receive routine angiographic follow-up at 9 months.
here were no significant differences for either the PES or
MS groups in terms of MACE or ARC ST according to
he performance of routine angiographic follow-up (Fig. 5).
owever, as previously reported at 1 year (14), the perfor-
ance of routine angiographic follow-up did lead to com-
arable trends for increased TLR in both groups at 5 years
PES: 10.7% angiographic vs. 6.9% nonangiographic; p 
.09; BMS: 23.4% angiographic vs. 16.9% nonangio-
raphic; p  0.07; multivariate p value for interaction 
.77).
aseline factors associated with MACE and TVR through
years. Multivariable analysis showed that PES use com-
ared with BMS use was associated with a significant
eduction in MACE over 5 years of follow-up (p  0.002)
Table 3). The risk of MACE strongly correlated with the
Table 4. Baseline Factors Associated With TVR at 5 Years
Baseline Variable* Coefficient
Odds Ratio
(95% CI) p Value
Overall population
Treatment with PES 0.60 0.55 (0.41–0.73) 0.0001
Diabetes requiring medication 0.54 1.72 (1.26–2.34) 0.0006
Maximum stent expansion diameter 0.65 0.52 (0.34–0.80) 0.003
Lesion angulation 0.01 0.99 (0.98–0.99) 0.004
Family history of CAD 0.40 1.48 (1.11–1.99) 0.008
Chronic heart failure 0.71 0.49 (0.25–0.97) 0.04
Acute gain 0.37 0.69 (0.48–0.99) 0.04
Vessel tortuosity 0.53 1.69 (1.00–2.88) 0.05
ACC/AHA Class C 0.29 1.34 (0.96–1.88) 0.09
Patients treated with BMS
Post-procedure in-stent MLD 0.85 0.43 (0.26–0.69) 0.0005
Diabetes requiring medication 0.56 1.75 (1.15–2.66) 0.009
Family history of CAD 0.50 1.65 (1.11–2.43) 0.01
Multiple study stents implanted 0.85 2.33 (1.13–4.83) 0.02
Lesion angulation 0.01 0.99 (0.98–1.00) 0.03
Chronic heart failure 0.96 0.38 (0.15–0.98) 0.04
Proximal/distal geographic miss 0.63 1.88 (0.99–3.54) 0.05
Left ventricular ejection fraction 0.02 1.02 (1.00–1.04) 0.06
Number of lesions treated 0.47 0.62 (0.37–1.06) 0.08
Patients treated with PES
Age 0.03 0.97 (0.95–0.99) 0.002
Maximum stent expansion diameter 0.81 0.44 (0.24–0.84) 0.01
Prior PCI 0.56 1.74 (1.10–2.76) 0.02
Angina class 3 or 4 0.55 1.74 (1.09–2.78) 0.02
Female sex 0.54 1.72 (1.06–2.79) 0.03
Diabetes requiring medication 0.49 1.63 (1.00–2.63) 0.049
Calciﬁcation† 0.50 1.65 (0.95–2.87) 0.07
*All variables with p 0.10 are shown. †Severe calcification was an exclusion criterion.MLDminimal lumen diameter; other abbreviations as in Tables 1, 2, and 3.
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1257umber of stents implanted (p  0.03), medically treated
iabetes (p  0.001), and smaller baseline RVD (p 
.005). Table 3 also displays the independent correlates of
ACE at 5 years in the BMS and PES groups separately.
n the overall population, treatment with PES, chronic
eart failure, and acute gain were strongly and significantly
orrelated with decreased TVR through 5 years, whereas a
amily history of coronary artery disease and diabetes requir-
ng medication were significantly associated with increased
VR at 5 years (Table 4). Table 4 also displays the
ndependent correlates of TVR at 5 years in the BMS and
ES groups separately.
atients with medically treated diabetes mellitus. A total of
63 patients in the BMS group and 152 patients in the PES
roup had medically treated diabetes. Higher rates of
ACE were noted in diabetic compared with non-diabetic
atients, in both the PES and BMS groups. Patients with
iabetes tended to have higher 5-year all-cause mortality for
oth BMS (13.1% diabetic vs. 10.5% nondiabetic; p 0.31)
nd PES (12.7% diabetic vs. 9.1% nondiabetic; p  0.18),
ith similar rates of MI and ARC definite/probable ST
Fig. 6). Patients treated with PES had a comparable and
Figure 6. Revascularization and Safety in the Diabetic Subset
Rates of (A) all death; (B) MI; (C) ARC ST deﬁnite/probable; and (D) TLR throug
out medically treated diabetes (DM). Abbreviations as in Figures 1 and 3.ustained approximately 50% reduction in TLR at 5 years
ompared with BMS, in both diabetic (27% BMS vs. 13%
ES; p  0.002) and nondiabetic patients (18% BMS vs.
% PES; p  0.0001). Although diabetic patients treated
ith PES had significantly lower rates of TLR compared
ith BMS, PES- and BMS-treated patients exhibited
imilar increases in the absolute rates of non-TL TVR,
eflecting more aggressive CAD beyond the stent and its
argins (Fig. 7). In the PES group, non-TL TVRs repre-
ented one-half of all TVRs at 5-year follow-up, compared
ith only 35% of the 5-year TVRs in the BMS group.
iscussion
n the pivotal TAXUS IV clinical trial, the use of PES
rovided a significant reduction in repeat revascularization
f both the target lesion and target vessel compared with
MS, which was evident at the 9-month primary time point
nd was sustained throughout 5-year follow-up. There were
omparable, low, and constant annualized hazard rates for
ew TLR and TVR events in both PES and BMS patients
ears in 315 patients with medically treated diabetes and 979 patients with-h 5 y
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1258etween years 1 and 5, with no evidence of late “catch-up”
n patients who received PES.
Although this study enrolled relatively low-risk patients
e.g., no recent MI, 34% enzyme-negative acute coronary
yndrome), comprising approximately 35% of the current
tent-treated population (6), and was underpowered to
etect differences in low-frequency events between treat-
ent groups, the careful long-term follow-up does allow for
ome important safety conclusions. Critically, safety pro-
les—including rates of death, MI, and ARC ST—
emained low and comparable between the PES and BMS
roups throughout the 5-year follow-up. Results from this
rial are generally similar to those from the recently reported
-year follow-up of the pivotal randomized trial comparing
he sirolimus-eluting stent with a BMS control (15). De-
pite earlier concerns about the incidence of VLST (events
ccurring after 1 year) with drug-eluting stents compared
ith BMS (4,16,17), and acknowledging previously noted
imitations in statistical power, this randomized, double-
lind study did not identify significant differences in ST
ates between PES and BMS at any time point (acute,
ubacute, late, or VLST). Over 5 years, the cumulative
ncidence of ARC definite/probable ST was 2.2% for PES
ersus 2.1% for BMS (p  0.87). Annualized hazard rates
or VLST were 0.4%/year for PES compared with 0.3%/
ear for BMS (p  0.45) between years 1 and 5 (7 of 625
MS patients, and 9 of 632 PES patients). A pooled
nalysis of 8 randomized, controlled trials comparing either
Figure 7. Revascularization Type in the Diabetic Subset
Relative contributions of TLR and non-TL TVR to the cumulative 5-year rate
of TVR. Patients might have had both TLR and non-TL TVR. Abbreviations
as in Figures 1 and 3.ES or sirolimus-eluting stent with BMS also found similar aumulative rates of ARC definite or probable VLST of 0.9%
or sirolimus-eluting stent versus 0.4% for BMS among
,748 patients and 0.9% for PES versus 0.6% for BMS
mong 2,797 patients, at 4 years of follow-up (16). Of
ourse, even these findings do not exclude a small potential
ncreased risk of VLST for drug-eluting stents compared
ith BMS, but no such difference between PES and BMS
as observed in the relatively noncomplex TAXUS IV
atient population. Long-term follow-up from additional
tudies are required to verify the late safety profile of PES in
ore complex patient cohorts.
Several baseline factors were significantly associated with
n increased risk of MACE at 5 years for the overall
opulation, including smaller baseline RVD, medically
reated diabetes, the total number of stents implanted, and
se of BMS rather than PES. In particular, the presence of
iabetes and greater number of stents implanted can be
onsidered as surrogate markers for more diffuse and rapidly
rogressive coronary artery disease, which might be ex-
ected to translate into an increased annual rate of late
dverse events (13). A pooled analysis of the TAXUS trials
as demonstrated that approximately one-half of all late
evascularizations after 1 year occur in nonstented segments
f the target vessels in both PES and BMS, highlighting the
mportance of aggressive risk-factor control in reducing this
ngoing manifestation of progressive atherosclerosis (13).
Routine angiographic follow-up has previously been
hown to increase the rate of revascularization compared
ith clinically driven follow-up. In this study, routine
ngiographic follow-up produced significant increases in
epeat revascularization at 1-year follow-up in both the PES
nd BMS patients (14), but those differences no longer were
tatistically significant at 5 years, given the ongoing accu-
ulation of non-TL TVR in both the routine angiographic
nd clinical follow-up only groups.
The presence of diabetes increased the rate of revascular-
zation in both the PES and BMS groups due to increased
ates of both TLR and TVR outside the stent and its 5-mm
argins (non-TL TVR) (Fig. 7), indicative of the more
ggressive coronary disease in diabetic patients (18,19).
owever, the 5-year rate of revascularization remained
ower in PES-treated diabetic patients, due to a significant
eduction in TLR by PES. Although total mortality was
lightly but not significantly increased in patients with
iabetes compared with those without diabetes, the rates of
I and ST did not differ between the PES and BMS
reatment groups according to diabetic status. These results
re consistent with an earlier pooled analysis of 3,513
atients treated with PES or BMS in relatively noncomplex
esions (20).
tudy limitations. The TAXUS IV study enrolled patients
ith relatively simple, uncomplicated lesions; as such, the
esults might not be applicable to more complex real-world
natomic or clinical populations. However, 35% of the
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1259eal-world ARRIVE registry population met the enrollment
riteria for TAXUS IV, suggesting that the findings of
AXUS IV do apply to a substantial number of real-world
atients (6). The outcomes in this “TAXUS IV-like”
ubpopulation of ARRIVE, moreover, were essentially su-
erimposable with those of the non-angiographic follow-up
ohort in TAXUS IV through 2 years. Finally, as previously
entioned, despite the substantial size of this pivotal
andomized controlled trial and the absence of signals of
ncreased ST, death, or MI through 5 years of follow-up for
ES versus BMS, it remains underpowered to study very
ow-frequency events.
onclusions
he 5-year results from the pivotal TAXUS IV trial
emonstrate sustained efficacy of PES in a diverse group of
atients with non-complex lesions, with no increase in
ong-term safety events compared with the otherwise iden-
ical BMS control.
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